Skip to main content
Hanshang Group Co.,Ltd. logo

Hanshang Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600774 ISIN · CNE000000NC5 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,577 across all filing types
Latest filing 2020-07-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600774

About Hanshang Group Co.,Ltd.

https://www.whhsg.com/

Hanshang Group Co.,Ltd. is a diversified enterprise focused on commercial operations, exhibition services, and healthcare. The company manages a portfolio of large-scale department stores, shopping malls, and specialized retail outlets. Its exhibition segment provides comprehensive venue management and event organization services for international and domestic trade fairs. Hanshang Group has significantly expanded its presence in the healthcare sector through the development and distribution of pharmaceuticals, medical devices, and health-related products. By integrating traditional commercial assets with modern biomedical research and health management services, the group targets a broad consumer base and professional medical markets, emphasizing a strategic transition toward a comprehensive health-oriented business model.

Recent filings

Filing Released Lang Actions
非公开发行股票预案
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and explanation for a non-public stock issuance by 汉商集团股份有限公司 (Hanshang Group Co., Ltd.). It includes extensive information about the background, purpose, issuance details, pricing, lock-up periods, use of proceeds, and impact on company control. It also discusses the acquisition of 100% equity in 成都迪康药业股份有限公司 (Chengdu Dikang Pharmaceutical Co., Ltd.) as part of the investment plan. The document references approvals needed from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and it is dated July 2020. The content is comprehensive and includes financial and strategic analysis related to the capital raising and asset acquisition. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an announcement of a report, nor a full annual or interim report, but a detailed issuance plan and related disclosures for a non-public stock offering and related major asset acquisition.
2020-07-28 Chinese
董事会关于本次交易符合《上市公司重大资产重组管理办法》第十一条规定的说明
M&A Activity Classification · 95% confidence The document is a statement from the board of directors of 汉商集团股份有限公司 regarding the compliance of a major asset restructuring transaction with the relevant regulatory provisions, specifically the 'Administrative Measures for Major Asset Restructurings of Listed Companies' Article 11. It discusses the legality, fairness, and compliance of the transaction but does not contain financial statements or detailed financial data. It is an announcement related to a corporate restructuring transaction rather than a full merger filing or a detailed financial report. This fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids, including major asset restructuring disclosures.
2020-07-28 Chinese
董事会关于本次重组符合《关于规范上市公司重大资产重组若干问题的规定》第四条规定的说明
Regulatory Filings Classification · 95% confidence The document is a formal statement from the board of directors of 汉商集团股份有限公司 regarding the compliance of a major asset restructuring transaction with regulatory provisions on major asset restructurings. It discusses the purchase of 100% equity of another company and confirms that the transaction meets specific regulatory requirements. The document is not a full financial report, audit, or earnings release, nor is it a voting result or proxy solicitation. It is a regulatory compliance explanation related to a major asset restructuring. Given the content and nature, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement explaining compliance with rules on major asset restructurings rather than the restructuring transaction announcement itself or a detailed M&A filing.
2020-07-28 Chinese
董事会关于公司股票价格波动是否达到《关于规范上市公司信息披露及相关各方行为的通知》第五条相关标准的说明
Regulatory Filings Classification · 95% confidence The document is a formal statement from the board of directors of 汉商集团股份有限公司 regarding whether the company's stock price fluctuation meets the criteria set out in a regulatory notice about information disclosure and related behaviors. It references specific regulatory guidelines (证监公司字 [2007]128 号) and provides analysis of stock price movements relative to market indices. The document is short (1187 characters) and serves as an explanatory note or announcement rather than a detailed financial report or audit. It does not contain financial statements or detailed management discussion. It is not a report publication announcement since it contains substantive explanation and analysis. The content fits best under Regulatory Filings (RNS) as it is a regulatory compliance disclosure related to stock price behavior and information disclosure rules.
2020-07-28 Chinese
董事会关于本次交易相关主体不存在依据《关于加强与上市公司重大资产重组相关股票异常交易监管的暂行规定》第十三条不得参与任何上市公司重大资产重组情形的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of 汉商集团股份有限公司 regarding the compliance of the parties involved in a major asset restructuring transaction with regulatory provisions related to insider trading and participation restrictions. It specifically addresses the absence of any investigation or penalties related to insider trading in the context of the asset restructuring. The document does not contain financial statements, detailed financial analysis, or a full report on the transaction. Instead, it is a regulatory compliance statement related to a major asset restructuring transaction. This type of document fits best under Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into more specific categories like M&A filings or audit reports.
2020-07-28 Chinese
关于本次重组采取的保密措施和保密制度的说明
Regulatory Filings Classification · 95% confidence The document is a formal statement from 汉商集团股份有限公司 regarding the confidentiality measures and confidentiality system adopted for a major asset restructuring involving the purchase of 100% equity of 成都迪康药业股份有限公司. It details the internal confidentiality protocols, limited information disclosure, and signing of confidentiality agreements in compliance with laws and regulations. The document does not contain financial data, results, or detailed transaction terms but focuses on the confidentiality aspect of the restructuring process. It is not a full merger or acquisition filing, nor a financial report or announcement of voting results. It is a regulatory announcement related to a corporate transaction emphasizing compliance and confidentiality. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-07-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.